PMC:7283670 / 55409-56573
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T201 | 543-548 | Body_part | denotes | chest | http://purl.org/sig/ont/fma/fma9576 |
| T202 | 886-890 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T133 | 543-548 | Body_part | denotes | chest | http://purl.obolibrary.org/obo/UBERON_0001443 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T339 | 79-87 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T340 | 120-128 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T341 | 1038-1046 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T342 | 1120-1128 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T536 | 140-142 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
| T537 | 347-348 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T538 | 543-548 | http://www.ebi.ac.uk/efo/EFO_0000965 | denotes | chest |
| T539 | 583-588 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T540 | 884-890 | http://purl.obolibrary.org/obo/CL_0000084 | denotes | T cell |
| T541 | 958-963 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
| T542 | 1008-1009 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T543 | 1066-1071 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
| T544 | 1139-1141 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T65175 | 33-36 | Chemical | denotes | TCM | http://purl.obolibrary.org/obo/CHEBI_145500 |
| T42271 | 95-98 | Chemical | denotes | TCM | http://purl.obolibrary.org/obo/CHEBI_145500 |
| T66 | 167-172 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T5227 | 185-188 | Chemical | denotes | TCM | http://purl.obolibrary.org/obo/CHEBI_145500 |
| T89603 | 201-209 | Chemical | denotes | medicine | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T64472 | 266-281 | Chemical | denotes | antiviral drugs | http://purl.obolibrary.org/obo/CHEBI_36044 |
| T16097 | 266-275 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T79085 | 276-281 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T84596 | 298-301 | Chemical | denotes | TCM | http://purl.obolibrary.org/obo/CHEBI_145500 |
| T22462 | 362-367 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T20379 | 377-385 | Chemical | denotes | medicine | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T7585 | 443-458 | Chemical | denotes | antiviral drugs | http://purl.obolibrary.org/obo/CHEBI_36044 |
| T86024 | 443-452 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T48066 | 453-458 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T54548 | 589-596 | Chemical | denotes | antigen | http://purl.obolibrary.org/obo/CHEBI_59132 |
| T38531 | 964-975 | Chemical | denotes | angiotensin | http://purl.obolibrary.org/obo/CHEBI_48433 |
| T17203 | 1072-1083 | Chemical | denotes | angiotensin | http://purl.obolibrary.org/obo/CHEBI_48433 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T607 | 1-353 | Sentence | denotes | Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day) |
| T608 | 354-494 | Sentence | denotes | Control group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): |
| T609 | 495-562 | Sentence | denotes | The relief/disappearance rate of main symptoms, chest CT absorption |
| T610 | 563-675 | Sentence | denotes | Secondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. |
| T611 | 676-799 | Sentence | denotes | The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score |
| T612 | 800-945 | Sentence | denotes | Other outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020 |
| T613 | 946-1053 | Sentence | denotes | Recombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1807 | 964-995 | Gene | denotes | angiotensin‐converting enzyme 2 | Gene:59272 |
| 1808 | 1072-1103 | Gene | denotes | angiotensin‐converting enzyme 2 | Gene:59272 |
| 1879 | 833-836 | Gene | denotes | CRP | Gene:1401 |
| 1880 | 958-963 | Species | denotes | human | Tax:9606 |
| 1881 | 1024-1032 | Species | denotes | patients | Tax:9606 |
| 1882 | 1066-1071 | Species | denotes | human | Tax:9606 |
| 2095 | 79-87 | Disease | denotes | COVID‐19 | MESH:C000657245 |
| 2096 | 120-128 | Disease | denotes | COVID‐19 | MESH:C000657245 |
| 2097 | 1038-1046 | Disease | denotes | COVID‐19 | MESH:C000657245 |
| 2098 | 1120-1128 | Disease | denotes | COVID‐19 | MESH:C000657245 |